U.S. Clinical Chemistry Analyzer Market
The U.S. clinical chemistry analyzer market is expected to reach USD 7.20 billion by 2031 from USD 5.40 billion in 2024, growing with the substantial CAGR of 3.9% in the forecast period of 2024 to 2031.
Market Segmentation: U.S. Clinical Chemistry Analyzer Market, By Product Type (Analyzers, and Reagents), Test Type (Metabolic Panel (BMP), General Chemistry Test, Liver Panel, Electrolyte Panel, Renal Profile, Lipid Profile, Specialty Chemical Tests, Thyroid Function Panel, and Others), Modality (Benchtop, Standalone, Portable, and Others), Application (Inflammatory Diseases, Diabetes, Cancer, Abuse of Drugs, Renal Failure, Cardiovascular Diseases, Nutritional Deficiency, and Others), Specimen (Serum, Plasma, Urine, Cerebrospinal Fluid (CSF), Amniotic Fluid, Saliva, Blood, and Others), End Users (Independent Diagnostic Laboratories (Laboratories Outside Hospitals, and Hospitals), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031
Overview of U.S. Clinical Chemistry Analyzer Market Dynamics:
Driver
• Increasing prevalence of chronic disease
Restrain
• High cost of analyzers
Opportunity
• Rise in preference for preventive health check ups
Market Players:
The key market players operating in the U.S. clinical chemistry analyzer market are listed below: • F. Hoffmann-La Roche Ltd
• Beckman Coulter, Inc. (Subsidiary of Danaher)
• Thermo Fisher Scientific Inc.
• Abbott
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• HORIBA
• ELITech Group
• Randox Laboratories Ltd.
• Medica Corporation
• JEOL Ltd.
• FURUNO ELECTRIC CO. LTD.
• Hitachi High-Tech Corporation
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.